Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 13/20 | 0.68 |
| ▸ | ECE1 | P42892 | 1/20 | 0.68 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.68 |
| ▸ | GCGR | P47871 | 1/20 | 0.64 |
| ▸ | GIPR | P48546 | 1/20 | 0.64 |
| ▸ | KISS1R | Q969F8 | 5/20 | 0.63 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.62 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.61 |
| ▸ | CCKBR | P32239 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423247 | 0.94 | GLP1R (0.73) | GLP1RECE1MUS81GCGRGIPR | |
| SCHEMBL29416056 | 0.92 | KISS1R (0.62) | GLP1RECE1MUS81KISS1RPTH1R | |
| SCHEMBL29358496 | 0.92 | GLP1R (0.68) | GLP1RECE1MUS81GCGRGIPR | |
| SCHEMBL31378965 | 0.92 | GLP1R (0.71) | GLP1RECE1MUS81IL23R | |
| SCHEMBL30506350 | 0.91 | GLP1R (0.68) | GLP1RECE1MUS81GCGRGIPR | |
| SCHEMBL30623138 | 0.91 | GLP1R (0.74) | GLP1RECE1MUS81PTH1RCCKBR | |
| SCHEMBL31182990 | 0.91 | GLP1R (0.70) | GLP1RECE1MUS81GCGRGIPR | |
| SCHEMBL31182873 | 0.91 | GLP1R (0.68) | GLP1RECE1MUS81GCGRGIPR | |
| SCHEMBL30576887 | 0.90 | GLP1R (0.68) | GLP1RECE1MUS81PTH1RIL23R | |
| SCHEMBL31092866 | 0.90 | IL23R (0.64) | GLP1RECE1MUS81GCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 527 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090605-A2 | COMPOSITIONS AND METHODS COMPRISING TARGETED LIPOSOMAL THERAPEUTIC VACCINES | DREXEL UNIVERSITY (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4631514-A1 | ORAL POLYPEPTIDE COMPOSITION AND USE THEREOF | Hefei Tianhui Biotech Co., Ltd. (CN) | 2025-10-15 | — | — | EP | claimed |
| EP-4566670-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| US-20250177373-A1 | COMPOSITIONS AND METHODS FOR TARGETING A VIRAL INFECTION | THE CHILDEREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-05 | — | — | US | claimed |
| US-20250170172-A1 | METHODS FOR TREATING LENTIVIRUS INFECTION | JERICHO SCIENCES LLC (US) | 2025-05-29 | — | — | US | claimed |
| US-12064425-B2 | Compositions and methods for targeting a viral infection | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2024-08-20 | — | — | US | claimed |
| EP-4403221-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2024120513-A1 | ORAL POLYPEPTIDE COMPOSITION AND USE THEREOF | 合肥天汇生物科技有限公司 | 2024-06-13 | — | — | WO | claimed |
| WO-2024012589-A1 | POLYPEPTIDE COMPOSITION, PHARMACEUTICAL, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 合肥天汇生物科技有限公司 | 2024-01-18 | — | — | WO | claimed |
| WO-2023164293-A1 | METHODS FOR VIRAL INFECTIONS | JERICHO SCIENCES, LLC (US) | 2023-08-31 | — | — | WO | claimed |
| US-12636279-B2 | Choline salt forms of an HIV capsid inhibitor | GILEAD SCIENCES, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2026090160-A2 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090605-A2 | COMPOSITIONS AND METHODS COMPRISING TARGETED LIPOSOMAL THERAPEUTIC VACCINES | DREXEL UNIVERSITY (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20220042064-A1 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | LONZA LTD (CH) | 2022-02-10 | — | — | US | disclosed |
| EP-3947695-A1 | MUT- METHYLOTROPHIC YEAST | Universität für Bodenkultur Wien (AT) | 2022-02-09 | — | — | EP | disclosed |
| CN-114026213-A | Continuous blade type impeller | 龙沙有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11236520-B2 | Customizable facility | LONZA LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3942014-A1 | CONTINUOUS BLADE IMPELLER | Lonza Ltd. (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170172-A1 | METHODS FOR TREATING LENTIVIRUS INFECTION | ZC3HAV1, ZC3HAV1L, ZFR | GLP1R 4140/4885ECE1 3206/4885MUS81 2486/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | GLP1R 319/4885ECE1 4008/4885MUS81 2751/4885 |
| US-12636279-B2 | Choline salt forms of an HIV capsid inhibitor | CHKA, SLC5A7, SLC44A1 | GLP1R 4779/4885ECE1 2329/4885MUS81 3559/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | GLP1R 4101/4885ECE1 1177/4885MUS81 3549/4885 |
| US-20250177373-A1 | COMPOSITIONS AND METHODS FOR TARGETING A VIRAL INFECTION | HAVCR2, CD4, MAVS | GLP1R 4274/4885ECE1 493/4885MUS81 671/4885 |
| US-12064425-B2 | Compositions and methods for targeting a viral infection | HAVCR2, CD4, MAVS | GLP1R 4274/4885ECE1 493/4885MUS81 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.